GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shanghai Junshi Biosciences Co Ltd (OTCPK:SHJBF) » Definitions » 3-Year Book Growth Rate

SHJBF (Shanghai Junshi Biosciences Co) 3-Year Book Growth Rate : -15.90% (As of Sep. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Shanghai Junshi Biosciences Co 3-Year Book Growth Rate?

Shanghai Junshi Biosciences Co's Book Value per Share for the quarter that ended in Sep. 2024 was $0.89.

During the past 12 months, Shanghai Junshi Biosciences Co's average Book Value per Share Growth Rate was -19.90% per year. During the past 3 years, the average Book Value per Share Growth Rate was -15.90% per year. During the past 5 years, the average Book Value per Share Growth Rate was 6.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 9 years, the highest 3-Year average Book Value per Share Growth Rate of Shanghai Junshi Biosciences Co was 65.60% per year. The lowest was -15.90% per year. And the median was 32.85% per year.

Competitive Comparison of Shanghai Junshi Biosciences Co's 3-Year Book Growth Rate

For the Biotechnology subindustry, Shanghai Junshi Biosciences Co's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Shanghai Junshi Biosciences Co's 3-Year Book Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Shanghai Junshi Biosciences Co's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where Shanghai Junshi Biosciences Co's 3-Year Book Growth Rate falls into.


;
;

Shanghai Junshi Biosciences Co 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

Shanghai Junshi Biosciences Co  (OTCPK:SHJBF) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

Shanghai Junshi Biosciences Co 3-Year Book Growth Rate Related Terms

Thank you for viewing the detailed overview of Shanghai Junshi Biosciences Co's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Shanghai Junshi Biosciences Co Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shanghai Junshi Biosciences Co Ltd (OTCPK:SHJBF) » Definitions » 3-Year Book Growth Rate
Comparable Companies
HKSE:01530 HKSE:01548 HKSE:09995 HKSE:09969 HKSE:02696 HKSE:01952 HKSE:06855 HKSE:06826 HKSE:02410 HKSE:02162 VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
01877:Hong Kong 8SJ:Germany 688180:China
Address
Nos. 36 and 58, Hai Qu Road, Room 1003, Level 10, Building 2, Pilot Free Trade Zone, Shanghai, CHN
Website
https://www.junshipharma.com
Shanghai Junshi Biosciences Co Ltd is a China-based biotechnology companyy with all-round capabilities in innovative drug discovery and development, clinical research on a global scale, large-scale production capacity to commercialization on the full industry chain. Aiming to develop first-in-class or bestin-class drugs by way of original innovation and co-development. Companies operations are located in the PRC and the USA.